within Pharmacolibrary.Drugs.ATC.L;

model L01EH01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 4.34 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 1250 / 1000000,
    adminCount     = 1,
    Vd             = 1.67,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0115,
    Tlag           = 20.400000000000002
  );

  annotation(Documentation(
    info ="<html><body><p>Lapatinib is an oral tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It is primarily used in the treatment of HER2-positive breast cancer, especially in combination with other chemotherapeutics. Lapatinib is approved for use in several countries, including the United States and the EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult female patients with advanced or metastatic HER2-positive breast cancer, following repeated oral administration.</p><h4>References</h4><ol><li><p>Yu, TW, et al., &amp; Sasaki, K (2024). Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration. <i>The Journal of veterinary medical science</i> 86(3) 317–321. DOI:<a href=&quot;https://doi.org/10.1292/jvms.23-0448&quot;>10.1292/jvms.23-0448</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38281758/&quot;>https://pubmed.ncbi.nlm.nih.gov/38281758</a></p></li><li><p>Koch, KM, et al., &amp; Bang, YJ (2015). Effect of lapatinib on oral digoxin absorption in patients. <i>Clinical pharmacology in drug development</i> 4(6) 449–453. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.189&quot;>10.1002/cpdd.189</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27137717/&quot;>https://pubmed.ncbi.nlm.nih.gov/27137717</a></p></li><li><p>Pai, SM, et al., &amp; Berg, JK (2019). Pharmacokinetics of Lapatinib, a Nonrenally Cleared Drug, in Patients With End-Stage Renal Disease on Maintenance Hemodialysis. <i>Journal of clinical pharmacology</i> 59(10) 1379–1383. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1430&quot;>10.1002/jcph.1430</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31074516/&quot;>https://pubmed.ncbi.nlm.nih.gov/31074516</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EH01;
